← All trials
NCT05550532
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2022
- Primary completion
- Oct 17, 2024
- Completion date
- Oct 17, 2024
- First posted
- Sep 22, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 830
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.